Faeth Therapeutics

Faeth Therapeutics is a healthcare start-up that uses precision nutrition and metabolism in order to fight cancer. The San Francisco-based company was founded in 2019 by former Virta Health CFO Anand Parikh and Oliver Maddocks, PhD, a Professor of Cancer Biology and Metabolism at the University of Glasgow. Parikh and Maddocks serve as Faeth's CEO and Head of Research, respectively. Faeth's founding scientific team includes Drs. Lew Cantley, Director Meyer Cancer Center, Weill Cornell Medicine; Sid Mukherjee, Oncologist at Columbia University Irving Medical Center and author; and Karen Vousden, Chief Scientist of Cancer Research UK and Group Leader at the Francis Crick Institute.

Faeth Therapeutics leverages precision nutrition and metabolism in an effort to effectively "starve" cancer of nutrients it needs to grow and resist treatment. The company envisions metabolism and precision nutrition as one day joining surgery, radiotherapy, small molecules (such as chemotherapy and targeted therapies), and biologics (such as immunotherapy and antibodies) as integral treatments to cancer. Faeth relies on a machine learning-driven precision nutrition platform it calls MetabOS. The goal is to analyze a cancerous tumor with MetabOS and in turn discover what nutrients the cancer feeds off of in order to grow. Faeth then would provide diets and supplements that are completely devoid of said nutrient in order to starve the tumor. After closing a $20 million seed round in January 2022, the company announced that it would be expanding and deepening its research, as well as further developing the MetabOS.

Faeth Therapeutics has participated in two funding rounds as of 2022. The latest was a $20 million seed round announced on January 18, 2022. The round was co-led by Khosla Ventures and Future Ventures, and included participation from S2G Ventures, Digitalis Ventures, KdT Ventures, AgFunder, Cantos Ventures and Unshackled Ventures.